IMvigor210, trial summary

A randomised clinical trial investigating the effect of atezolizumab versus nil in Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen

Studied treatment	Atezolizumab
Control treatment	single arm study

Patients	Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen
Group sizes	-9 / -9

Blindness	Inclusion period
Follow-up duration	Centers
Lost to FU	geographical localisation
Primary endpoint	Design	Single-arm study

phase 2

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67-76 [PMID: 27939400] link to pdf add to Mendeley

ClinicalTrial.gov record NCT02951767

Registering number	NCT02951767 (see trial on clinicaltrials.gov)
Code Name

IMvigor210, trial summary PDF trial summary